Medical XpressAutism Research Finds Phelan-McDermid Syndrome May Affect 1 in 7,300 People: More Common than Previously Thought

ℹ️ Observational Association Only Evidence

Researchers combined data from 10 independent genetic testing and autism research datasets comprising nearly 180,000 individuals with autism. After adjusting for undiagnosed cases and testing limitations, investigators estimated a prevalence of 13.7 cases per 100,000 people, or roughly 1 in 7,300 individuals.

Clinical Considerations

• SHANK3 deletions and mutations associated with Phelan-McDermid syndrome are estimated to account for up to 1% of autism spectrum disorder cases.
• Investigators estimated that more than 45,000 individuals in the United States may be living with the condition.
• Many developmental and autism patients may never receive adequate genetic testing, creating substantial diagnostic gaps.
• Ongoing precision-medicine and disease-targeted clinical trials increase the potential importance of earlier genetic identification.

Practice Applications

• Recognize genetic testing as an important component of autism evaluation.
• Interpret prevalence estimates within the context of modeling assumptions and diagnostic limitations.
• Monitor emerging clinical trials targeting SHANK3-related disease biology.
• Consider the role of genetic diagnosis in connecting patients with research and specialty resources.